Australia - angielski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - lixisenatide -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - lixisenatide -

Izrael - angielski - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 150 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Izrael - angielski - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 75 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - peppermint oil - gastro-resistant capsule, soft - 0.2 millilitre(s) - other drugs for functional gastrointestinal disorders

Izrael - angielski - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - film coated tablets - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - secondary prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

Izrael - angielski - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - solution for injection - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - treatment should be initiated and normally monitored only under hospital or specialist supervision. amiodacore injection is indicated for corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.amiodacore intravenous can be used where a rapid response is required or where oral administration is not possible.